Gardasil Causes 400 Percent More Deaths than Other Common Vaccine
Wednesday, July 29, 2009 by: David Gutierrez
(NaturalNews) A federal report has concluded that the human
papillomavirus (HPV) vaccine Gardasil has a 400 percent higher rate of
adverse effects than another comparable vaccine, the Menactra
anti-meningitis shot.
"It is unusual for there to be such a big
discrepancy between two vaccines used in similar populations involving
serious and relatively rare life threatening adverse events and
autoimmune disorders," the researchers from the federal Vaccine Events
Reporting System wrote.
Gardasil, marketed by Merck, prevents againt the strains of HPV believed to be responsible for 70 percent of cervical cancer
cases and 90 percent of genital warts cases. GlaxoSmithKline's
competing Cervarix vaccine protects against the same cervical
cancer-causing strains.
The researchers considered Gardasil
and Menactra equivalent for the purposes of comparison because they are
given to similar age groups at similar frequencies. Their study
concluded that Gardasil was associated with twice as many emergency
room visits, four times as many deaths, four times as many heart attacks,
seven times as many "disabled" reports and 15 times as many strokes.
All reported cases of blood clots and heart attacks associated with
Gardasil occurred when the vaccine was given alone, not in conjunction
with other drugs.
"Fainting, which has been attributed by
doctors and health officials as 'fear' of needles in teenage girls, is
reported six times as often ... after receipt of Gardasil than Menactra
even though Menactra is also given to girls in the same age group," the
researchers noted.
The report recommends that the government
more thoroughly investigate reports of dangerous side effects from the
HPV vaccine, that research be conducted into mechanisms by which the
vaccine might cause these effects, and that patients and parents be
more adequately warned of the risks before vaccination. It also
recommends that Congress investigate how the vaccine was fast-tracked
for approval in the absence of safety data on girls younger than 17.
